Expect to maintain muscle, not gain significantly, during active weight loss
While GLP-1 drugs are not yet FDA-approved specifically for alcohol use disorder, prescribers can discuss off-label use in appropriate clinical contexts
Dulaglutide, liraglutide and subcutaneous semaglutide have been approved for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus with established cardiovascular disease, dulaglutide is approved for use in type 2 diabetes mellitus with multiple risk factors, and both liraglutide and semaglutide have been approved for chronic weight management
These calculations are based on a 100-unit insulin syringe where 1 mL equals 100 units
GLP-1 agonists bind to the GLP-1 receptor and stimulate it to produce a physiological response, such as an increase in insulin sensitivity or appetite suppression
However, their release mechanism is more closely tied to ambient glucose levels, making their action more calibrated to actual need